Syncona enters kidney disease space with gene therapy newco Purespring

The launch of Purespring Therapeutics marks the next phase of Syncona’s strategy in moving gene therapy from targeting rare monogenic diseases to more complex, highly prevalent settings.

On Thursday, Syncona Ltd. (LSE:SYNC) launched its sixth adeno-associated viral (AAV) gene therapy company Purespring with a £45 million ($59.4 million) tranched series A round. The deal will give the firm an 84% stake in the start-up once all of the round has been allocated...